What is the better formulation of microencapsulated potassium chloride?

  • G. Simoneau
  • J. F. Bergmann
  • R. Pamphile
  • C. Caulin
  • J. M. Segrestaa
Article
Received:
  • 36 Downloads

Summary

A single blind cross-over study was performed comparing a new microencapsulated potassium chloride tablet (MET) with two reference formulations of oral potassium, namely potassium chloride solution (PS), and microencapsulated potassium chloride capsules (MEC), in 18 normal healthy volunteers.

The potassium chloride induced change in gastric potential difference (PD) of the mucosa was the main criterion of comparison and was assessed by the area above curve (AAC), the total duration of the effect (TDE), the maximal variation of PD (ΔMAX), and the aggression index (AI).

The results showed that all three formulations induced a fall in PD; the ΔMAX and AAC were significantly greater for PS indicating a higher aggressive effect of the solution; MET had significantly less aggressive effect than MEC when assessed by all parameters.

Keywords

Potassium chloride microencapsulation formulations gastric potential difference 
This is a preview of subscription content, log in to check access.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Nardone D., McDonald W., Girard D. (1978): Mechanisms in hypokalaemia: clinical correlation. Medicine, 57, 435–446.CrossRefPubMedGoogle Scholar
  2. 2.
    Lawson D., Henry D., Lowe J., Gray J., Morgan H. (1979): Severe hypokalaemia in hospitalized patients. Arch. Intern. Med. 139, 978–980.CrossRefPubMedGoogle Scholar
  3. 3.
    Katsikas J.L., Goldsmith C. (1971): Disorders of potassium metabolism. Med. Clin. North. Am., 55, 503–512.PubMedGoogle Scholar
  4. 4.
    Skoutakis V.A., Acchiardo S.R., Wojciechowski N.J., Carter A.C. (1984): Liquid and solid potassium chloride: bioavailability and safety. Pharmacotherapy, 4, 392–397.PubMedGoogle Scholar
  5. 5.
    Schwartz W. (1974): Disorders of fluid, electrolyte and acid base balance. In: Beeson P., McDerriot W. (eds). Textbook of Medicine 13th edn. Philadelphia, WB Saunders, p. 1627.Google Scholar
  6. 6.
    Ben-Ishay D., Engelman K. (1973): Bioavailability of potassium from a slow-release tablet. Clin. Pharmacol. Ther., 14, 250–258.PubMedGoogle Scholar
  7. 7.
    Skoutakis V.A., Acchiardo S.R., Wojciechowski N.J., Carter C.A., Melikian A.P., Chrenos A.N. (1985): The comparative bioavailability of liquid, wax matrix and microencapsulated preparation of potassium chloride. J. Clin. Pharmacol., 25, 619–621.PubMedGoogle Scholar
  8. 8.
    Stanaszek W.F., Romankiewicz J.A. (1985): Current approaches to management of potassium deficiency. Drug Intell. Clin. Pharm., 19, 176–184.PubMedGoogle Scholar
  9. 9.
    Dickerson K., Bressler R., Gelderman G., Cohn J., Goldstein J. (1980): Bioavailability efficiency, safety and acceptance of Klotrix, a slow-release potassium chloride supplement. Curr. Ther. Res., 28, 340–354.Google Scholar
  10. 10.
    Hutcheon D. (1976): Benefit-risk factors associated with supplemental potassium therapy. J. Clin. Pharmacol., 16, 85–87.PubMedGoogle Scholar
  11. 11.
    McMahon F.G., Akdamar K., Ryan J.R., Ertan A. (1982): Upper gastrointestinal lesions after potassium chloride supplements: a controlled clinical trial. Lancet, ii, 1059–1061.CrossRefGoogle Scholar
  12. 12.
    Melikian A.P., Cheng L.K., Wright G.J., Cohen A., Bruce R.E. (1988): Bioavailability of potassium from three dosage forms: suspension, capsule and solution. J. Clin. Pharmacol., 28, 1046–1050.PubMedGoogle Scholar
  13. 13.
    Caplain H., Dahan R., Pamphile R., Thebault J.J. (1991): A single blind normal volunteer bioavailability study of a new microencapsulated potassium chloride tablet compared with two reference potassium formulations. Eur. J. Drug Metab. Pharmacokinet., 16, 3, 241–244.PubMedGoogle Scholar
  14. 14.
    Hey H., Wamberg T., Rasmussen M., Jorgensen F. (1987): Endoscopic evaluation of potentially ulcerogenic drugs. Eur. Surg. Res., 19, 312–317.CrossRefPubMedGoogle Scholar
  15. 15.
    Lech Y., Hey H., Jorgensen F., Matzen P., Ostergaard O. (1987): Evaluation of ulcerogenic effect of potassium chloride by endoscopy and fecal blood loss. J. Clin. Pharmacol., 27, 206–209.PubMedGoogle Scholar
  16. 16.
    Isal J.P., Caulin C., Simoneau G., Dahan R. (1984): La mesure de la différence de potentiel gastrique induite pas l’aspirine. Un modèle d’étude pharmacologique des pansements gastriques chez l’homme. Thérapie, 39, 7–11.PubMedGoogle Scholar
  17. 17.
    Laule H., Lücker P.W., Altmayer P., Eldon M.A. (1982): Gastric potential difference as a model in clinical pharmacology: assessment of gastric mucosal response to aspirin. Eur. J. Clin. Pharmacol., 22, 147–151.CrossRefPubMedGoogle Scholar
  18. 18.
    Geall M.G., Philipps S.F., Summerskill W.H.J. (1970): Profile of gastric potential difference in man. Effects of aspirin, alcohol, bile and endogenous acid. Gastroenterology, 58, 437–443.PubMedGoogle Scholar
  19. 19.
    Murray H.S., Strottman M.P., Cooke A.R. (1974): Effect of several drugs on gastric potential difference in man. BMJ, 1, 19–21CrossRefPubMedGoogle Scholar
  20. 20.
    Ivey K.J., Paone D.B., Krause W.J. (1980): Acute effect of systemic aspirin on gastric mucosa in man. Dig. Dis., 25, 97–99.CrossRefGoogle Scholar
  21. 21.
    Smith B.M., Skillman J.J., Edwards B.G., Silen W. (1971): Permeability of the human gastric mucosa. Alteration by acetylsalicylic acid and ethanol. N. Engl. J. Med., 285, 716–721.PubMedGoogle Scholar
  22. 22.
    Baskin W.M., Ivey K.J., Krause W.J., Jeffrey G.E., Gemmel R.T. (1976): Aspirin-induced ultrastructural changes in human gastric mucosa. Correlation with potential difference. Ann. Intern. Med. 85, 299–303.PubMedGoogle Scholar
  23. 23.
    Stern A.I., Hogan D.L., Isenberg J.I. (1984): A new method for quantification of ion fluxes across in vivo human gastric mucosa: effect of aspirin, acetaminophen, ethanol and hyperosmolar solutions. Gastroenterology, 86, 60–70.PubMedGoogle Scholar
  24. 24.
    Bergmann J.F., Caulin C., Simoneau G., Dorf G., Segrestaa J.M. (1988): Persistent gastric-protective effect of antacid evaluated by measurement of transmucosal gastric potential difference. Clin. Pharmacol. Ther., 44, 546–549.PubMedGoogle Scholar
  25. 25.
    Bergmann J.F., Simoneau G., Chantelair G., Caulin C., Segrestaa J.M. (1989): Use of dimethicone to reduce the fall in gastric potential difference induced by bile salts. Eur. J. Clin. Pharmacol., 36, 379–381.CrossRefPubMedGoogle Scholar
  26. 26.
    Graham D.Y., Smith J.L., Jones R.D., Rakhit A., Tipnis V., Hurley M.E. (1987): Gastroscopic localization of a microencapsulated KCl preparation in the human stomach. Gastrointest. Endosc., 33, 220–223.CrossRefPubMedGoogle Scholar
  27. 27.
    Graham D.Y., Smith J.L., Bouvet A.A. (1990): What happens to tablets and capsules in the stomach: endoscopic comparison of disintegration and dispersion characteristics of two microencapsulated potassium formulations. J. Pharm. Sci., 79, 420–424.CrossRefPubMedGoogle Scholar
  28. 28.
    Hey H., Matzen P., Andersen J.T., Didriksen E., Nielsen B. (1979): Gastroscopic and pharmacological study of the disintegration of capsules and tablets. Br. J. Clin. Pharmacol., 8, 237–242.PubMedGoogle Scholar

Copyright information

© Springer-Verlag 1994

Authors and Affiliations

  • G. Simoneau
    • 2
  • J. F. Bergmann
    • 2
  • R. Pamphile
    • 1
  • C. Caulin
    • 2
  • J. M. Segrestaa
    • 2
  1. 1.Laboratoires LeoMontigny-le-BretonneuxFrance
  2. 2.Clinique ThérapeutiqueHôpital LariboisièreParis Cedex 10France

Personalised recommendations